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Diabetes mellitus is a common endocrine disorder characterized by hyperglycemia and long-term 
complications affecting the eyes, nerves, blood vessels, skin and kidneys. Increased glycation of proteins 
and accumulation of advanced glycation endproducts (AGEPs) have been implicated in the pathogenesis 
of diabetic complications. Glycation and AGEP formation are also accompanied by the formation of free 
radicals via autoxidation of glucose and glycated proteins. Compounds with combined antiglycation and 
antioxidant properties may offer therapeutic potential. Since the antioxidant activity of different extracts 
and fractions of aerial parts of Otostegia persica has been evaluated and this plant is used as an 
antidiabetic agent in Iranian traditional medicine, we evaluated the antiglycation activity of this species. 
Here, we report the isolation of known compound 3´, 7-dihydroxy-4´,6,8-trimethoxy-flavone for the 
antiglycation properties of this plant. 
 





Diabetes mellitus is an endocrine disorder characterized 
by chronic hyperglycemia which results for a deficiency of 
or resistance to insulin. Diabetes affects 1-2% of the 
population and there are around 100 million worldwide. 
This figure is expected to double over the next 10-15 
years. Individuals affected by diabetes are prone to 
complications such as retinopathy, cataract, neuropathy, 
atherosclerosis, nephropathy, embryopathy and wounds 
(Muhammed Saeed and Nessar, 2006). 
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Abbreviations: DMSO, Dimethyl sulfoxide; BSA, bovine serum 
albumin; TCA, trichloroacetic acid; AGEs, advanced glycation 
endproducts. 
sugar and free amino group of proteins, also known as 
Millard reaction, leads to the formation of glycated protein 
termed Amadori product. Further rearrangement, oxidation 
and   reduction   of   the  Amadori  products  result  in  the 
formation of several advanced glycation end products 
(AGEs) such as pentosidine, carboxymethyllysine, crossline 
and pyralline. Some of these products can react with a 
free amino group nearby and form crosslinking between 
proteins (Ulrich and Cerami, 2001). The crosslinked 
protein, example, crosslinked collagen are postulated to 
confer pathological conditions found in patients with 
diabetes and aging, such as arterial stiffness and decreased 
myocardial compliance, resulting from the loss of collagen 
elasticity (Singh et al., 2001; Aronson, 2003). Thus, 
agents that inhibit the formation of AGEs are purported to 
have therapeutic potentials in patients with diabetes and 
age-related disease.  
The oxidation process is believed to  play  an  important 
role in AGEs formation. Further oxidation of Amadori 




product leads to the formation of intermediate carbonyl 
compounds that can react with the nearby lysine or 
arginine residues to form protein crosslink and AGEs. 
The reactive carbonyl compounds may also be generated 
from the metal ion-catalyzed autooxidation of glucose 
(Rahbar and Figarola, 2003; Voziyan et al., 2003). 
Therefore, agents with antioxidative  or  metal-chelating 
property may retard the process of AGEs formation by 
preventing further oxidation of Amadori product and 
metal-catalyzed glucose oxidation (Jedsadayanmata, 
2005). In this regard, several natural compounds known 
to possess antioxidative property, such as flavonoid-rich 
extracts, have been shown to prevent AGEs formation. 
Otostegia persica (Lamiaceae) locally called "Golder", 
is widely distributed in south and southeastern of Iran. It 
is traditionally used for the treatment of malaria, fever and 
diabetes. The antioxidant activity of the different extracts 
and fractions of aerial parts of O. persica has been 
evaluated (Yassa et al., 2005) and since this plant is 
traditionally used in patients with diabetes, we investigated 
the antiglycation activity of O. persica. Here, we report 3´, 
7-dihydroxy-4´,6,8-trimethoxy-flavone as the active com-
pound for antiglycation property of this plant. 
 
 
MATERIALS AND METHODS 
 
Chemicals and general experimental procedure 
 
BSA (Bovine serum albumin) was purchased from the Research 
Organics Cleveland USA, while other chemicals (glucose anhydrous, 
trichloroacetic acid (TCA), sodium azide (NaN3), dimethyl sulfoxide 
(DMSO), sodium dihydrogen phosphate (Na2HPO4), potassium 
chloride (KCl), potassium dihydrogen phosphate (KH2PO4) and 
sodium hydroxide (NaOH) were purchased from Sigma Aldrich. 
Sodium phosphate buffer (pH 7.4) was prepared by mixing 
Na2HPO4 and NaH2PO4 (67 mM) containing sodium azide ( 3 mM), 
phosphate buffer saline (PBS) (pH 10) was prepared by mixing 
NaCl (137 mM) + Na2HPO4 (8.1 mM) + KCl (2.68 mM) + KH2PO4 
(1.47 mM) + pH 10 was adjusted with NaOH (0.25 mM), while BSA 
(10 mg/ml) and glucose anhydrous (50 mg/ml) solutions were 
prepared in sodium phosphate buffer. 
The FT IR spectra were recorded on a vector 22 instrument. The 
¹H-NMR was recorded on a Bruker AMX 500 NMR (Avance) 
instruments using the UNIX data solvent. ¹H-¹³C HMBC and HMQC 
were recorded at 500 MHz (proton) and 125 MHz (carbon), 
respectively. EI MS spectra were recorded on a Finnigan MAT 312. 
FAB mass measurements were performed on Jeol JMS HX 110 
mass spectrometer using glycerol as the matrix. HREI MS was 
carried out on Jeol JMS 600 mass spectrometer. Column chromato-





The plant, O. persica (Lamiaceae) was collected from Bandar Abbas, 
Hormozgan province, Iran, in May 2008 and identified by Mr. M. 
Kamalinezhad at the Department of Pharmacognosy, Faculty of 
Pharmacy, Shaheed Beheshti University of Medical Sciences, 
Tehran, Iran.  
A voucher specimen (No. 1719) has been deposited in the 
herbarium of the Department of Pharmacognosy, Faculty of Pharmacy, 







The air dried flowering aerial parts of O. persica (8 kg) was exhaus-
tively extracted by maceration with EtOH 80% (3 × 80 lit). 
The extract was evaporated to yield the residue (1112 g) which 
was partitioned between water (72 g), petroleum ether (188 g), 
CH2Cl2 (380 g), EtOAc (276 g) and n-butanol (132 g). The CH2Cl2  
fraction had significant antiglycation, so we subjected it to silica gel 
chromatography using petroleum ether with a gradient of CH2Cl2 up 
to 100% and followed by methanol. Six fractions were collected. As 
fraction No. 5 had antiglycation activity, we loaded it on silica gel 
and eluted with petroleum ether-EtOAc in increasing order of 
polarity to provide two fractions with petroleum ether/EtOAc 76:24 
and 81:19. 
Since the second fraction was active, it was rechromatographed 
over silica gel and eluted with petroleum ether/EtOAc (58:42 and 
52:48) to purify compound 3´, 7-dihydroxy-4´,6,8-trimethoxy-flavone 
(128 mg) which exhibited a very good antiglycation activity. 
 
 
In vitro glycation assay 
 
60 l of sample was prepared by dissolving in DMSO and sample 
mixture (20 l BSA + 20 l of glucose anhydrous + 20 l test 
sample). Glycated control contain 20 l BSA + 20 l glucose + 20 l 
sodium phosphate buffer, while blank control contains 20 l BSA 
and 40 l sodium phosphate buffer. After incubation in 96 well 
plates at 37°C for 7 days, samples are taken out and cooled at 
room temperature. After incubation, 60 l 100% TCA was added in 
each well and centrifuged (15000 rpm) for 4 min at 4°C. After 
agitation and centrifugation at 14000 rpm for 4 min, the supernatant 
containing glucose, inhibitor and interfering substance was 
removed and pellet contains AGE-BSA were dissolved in PBS. 
Assessment of fluorescence spectrum (ex. 370 nm) and change in 
fluorescence intensity (ex. 370 nm to 440 nm) based on AGEs were 
monitored by using Spectrofluorimeter RF-1500 (Shimadzu, Japan). 
% inhibition was calculated through the following formula. Rutin is 
used as the standard inhibitor. The comparison of fluorescence 
intensity at 370 nm Excitation and Emission at 440 nm is obtained 
by using Spectrofluorimeter. 
The results are reported in % inhibition = 100 - [(OD (test) / OD 
(blank)] x 100 
 
 
RESULTS AND DISCUSSION 
 
The active compound was isolated as pale yellow needles 
and identified as 3´,7-dihydroxy-4´,6,8-trimethoxy-flavone 
by X-ray Crystallography (Figure 1). Despite the structure 
elucidation by X-ray Crystallography, we report the 1H-
NMR and 13C-NMR data of this compound (Tables 1 and 
2). 3´,7-dihydroxy-4´,6,8-trimethoxy-flavone has exhibited 
a good antiglycation activity. It was observed that this 
compound at 3 mM concentration has shown 65% 
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Table 1. 1H-NMR (CDCl3) data of 3´, 7-dihydroxy-4´,6,8-
trimethoxy-flavone.  in ppm, J in Hz. 
 
Position  ¹H-NMR 
C (2) - 
H–C (3)  6.54 (1H, s) 
C (4) - 
C (5) - 
C (6) - 
C (7) - 
C (8) - 
H–C (9) 6.51 (1H, s) 
C (10) - 
C (1´) - 
H–C (2´) 7.43 (1H, d, J=2.1) 
C (3´) - 
C (4´) - 
H–C (5´) 6.91 (1H, d, J = 8.4) 
H–C (6´) 7.39 (1H, dd, J = 8.4, 2.1) 
MeO (11) 3.95 (3H, s) 
MeO (12) 3.90 (3H, s) 
MeO (13) 3.94 (3H, s) 
Table 2. ¹³C-NMR (CDCl3) data of 3´, 7-dihydroxy-4´,6,8-
trimethoxy-flavone.  in ppm. 
 
Carbon No. ¹³C-NMR 
C (2) 163.8 
C (3) 104.5 
C (4) 182.6 
C (5) 153.2 
C (6) 132.7 
C (7) 153.0 
C (8) 158.7 
C (9) 90.6 
C (10) 106.2 
C (1´) 124.5 
C (2´) 112.3 
C (3´) 146.1 
C (4´) 149.6 
C (5´) 110.7 
C (6´) 119.0 
MeO (11) 56.3 
MeO (12) 60.8 
MeO (13) 56.1 
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